Interrupted glucagon signaling reveals hepatic cell axis and role for l-glutamine in cell proliferation
Early data suggests that while retatrutide produces more dramatic weight loss, the gastrointestinal side effect patterns may differ from those seen with semaglutide alone
conducted target trial emulations comparing dual GLP-1/GIP agonists to GLP-1 monotherapy in patients with type 2 diabetes, finding that dual agonists were linked to numerically lower risks of MALOs, although confidence intervals overlapped, suggesting that extended observation period and larger patient cohorts may be needed to definitively establish comparative effectiveness [61]
The Journey Card serves as a personal history, combining photos, weight, and symptom entries to allow users to see trends over time rather than just random data points
Wong MC, McCarthy C, Fearnbach N, Yang S, Shepherd J, Heymsfield SB